Recent Blood Test Research Could Revolutionise Cancer Screening

It is no secret that cancer screening tests play an active and important role in optimising one’s health. Throughout the years, cancer screening tests have proven to be quite controversial in nature, however nonetheless they have remained a necessary part of healthcare when they are warranted. Screening tests are designed to pick up on abnormalities in the body that are not aesthetically obvious from the outside, or otherwise so easily noted. While there are individuals who insist that screening tests do more harm than good, there is the awareness that sometimes a screening test can mean the difference between early detection and later diagnosis. And at the end of the day, that is something that cannot and should not be ignored.
It is never an enjoyable experience to get a screening test, especially if the screening test in question is in relation to cancer in some way. These types of screening tests are among the most uncomfortable, the most challenging to endure. However, they are genuinely necessary sometimes to figure out what is going on below the surface level of the skin. Now, recent cancer research findings indicate that a new blood test could revolutionise cancer screening.
The blood test that could revolutionise cancer screening
Recent cancer research found that a new blood test that is currently in development has shown the ability to successfully screen for multiple types of cancer in the body. Further, this same blood test has been proven to have a high degree of accuracy, according to trials for the test that have been undertaken in October. This test looks for DNA (which cancerous cells dispel into the blood of the patient as the cells die). The biggest difference here is that liquid biopsies detect genetic mutations in the DNA, while this new blood test focuses on the changes in DNA, known as “methyl groups”.
These methyl groups are chemical compounds that often attach to DNA strands, ultimately controlling the genes that are “on” and “off”. This is a process known as methylation. This is significant because abnormal patterns in methylation often end up being more indicative of cancer types, than mutations of DNA are. This new blood test focuses where unusual patterns and displays on sections of genomes where abnormal methylation patterns.
Why this advancement matters so much
Essentially, this new blood test is an incredibly promising step forward in cancer screening research. If the test continues to develop positively and successfully, it will spell the beginning of a new era in cancer screening test – an era that could very likely change cancer screening tests forever. Knowing the importance of staying on top of these types of screening tests when they are warranted is one thing, but knowing that there is likely going to be a better, more effective way to undergo these types of test in the near future, is not only promising but potentially life-changing for cancer research not just now, but going forward into the future. To find out more information on medical tests and screening, go here

  1. cancer